Target intelligence / Profile preview

Dietary phosphate (Pi) (Pi)

Target
Pi
Molecular classification
Inorganic ion, Dietary nutrient, Other
01

Overview

Dietary phosphate refers to the inorganic phosphorus compounds ingested through food that are absorbed in the gastrointestinal tract, primarily in the duodenum and jejunum [1, 2]. In healthy individuals, the kidneys maintain phosphate homeostasis by excreting excess amounts; however, in patients with chronic kidney disease (CKD), this excretory capacity is severely diminished, leading to hyperphosphatemia [2, 4]. Elevated serum phosphate levels are a primary driver of secondary hyperparathyroidism, renal osteodystrophy, and systemic vascular calcification, which significantly increases cardiovascular mortality [2, 4]. To manage these risks, dietary phosphate is targeted within the gut lumen using non-absorbable binding agents such as sevelamer carbonate [1, 3]. These agents contain functional groups, like protonated amines, that ionically bind phosphate ions to form insoluble complexes, preventing their absorption and facilitating their excretion in the feces [1, 3]. By sequestering phosphate before it enters the bloodstream, these therapies help maintain mineral balance and mitigate the progression of CKD-related complications [1, 2]. This approach is essential for patients on dialysis who cannot otherwise regulate phosphorus levels through diet alone [1, 4].

Other names
Inorganic phosphateOrthophosphatePhosphorusIntestinal phosphatePO4
02

Mechanism of action

Sevelamer carbonate acts as a non-absorbed phosphate binder; it contains multiple amines that become protonated in the gastrointestinal tract, allowing them to bind dietary phosphate through ionic and hydrogen bonding, thereby preventing its absorption into the bloodstream [1, 3].

03

Biological functions

Bone mineralizationEnergy metabolismCell signalingAcid-base homeostasisOther
04

Disease associations

HyperphosphatemiaChronic kidney disease (CKD)Secondary hyperparathyroidismCardiovascular diseaseOther
05

Safety considerations

Gastrointestinal distress (constipation, nausea, vomiting) [1, 2]Bowel obstruction or perforation [1]Metabolic acidosis (more common with hydrochloride salt) [1, 2]Reduced absorption of fat-soluble vitamins (A, D, E, K) [1]Drug-drug interactions due to binding of co-administered medications like ciprofloxacin or levothyroxine [1, 3]
06

Interacting drugs

Sevelamer carbonate

6 more in the full profile.

07

Biomarkers

Serum phosphorusSerum calciumParathyroid hormone (PTH)Fibroblast growth factor 23 (FGF23)

Beyond the preview

Go deeper on Dietary phosphate (Pi) (Pi).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dietary phosphate (Pi) (Pi).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call